Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

#083: ECTRIMS Special on De-escalation and discontinuation of therapies for MS – What does it mean and how can it work?

33:08
 
Share
 

Manage episode 445381068 series 3562061
Content provided by Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

When can we consider de-escalation or even discontinuation of a high-efficient immunotherapy for MS without risking a disease worsening?

You can read the full article on my blog: https://ms-perspektive.com/83-deescalation

Hello and welcome to another summary of ECTRIMS 2024, this time on the topic of de-escalation and discontinuation of therapy. There was a scientific session on this topic with six lectures, moderated by Dr. Melinda Magyari and Prof. Bernhard Hemmer. And there were also individual posters. Except for one talk about NMOSD and MOGAD, all scientific contributions were about multiple sclerosis.

I will present all the contributions and their results, some of which are still preliminary. After all, it is a topic that probably affects most of us. Can or should I switch my therapy from a high efficacy to a lower one or even stop it altogether at some point, and when is that a safe approach?

Table of Contents

---

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.

  continue reading

105 episodes

Artwork
iconShare
 
Manage episode 445381068 series 3562061
Content provided by Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

When can we consider de-escalation or even discontinuation of a high-efficient immunotherapy for MS without risking a disease worsening?

You can read the full article on my blog: https://ms-perspektive.com/83-deescalation

Hello and welcome to another summary of ECTRIMS 2024, this time on the topic of de-escalation and discontinuation of therapy. There was a scientific session on this topic with six lectures, moderated by Dr. Melinda Magyari and Prof. Bernhard Hemmer. And there were also individual posters. Except for one talk about NMOSD and MOGAD, all scientific contributions were about multiple sclerosis.

I will present all the contributions and their results, some of which are still preliminary. After all, it is a topic that probably affects most of us. Can or should I switch my therapy from a high efficacy to a lower one or even stop it altogether at some point, and when is that a safe approach?

Table of Contents

---

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.

  continue reading

105 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play